Thiazolidinediones for the prevention of diabetes in the non‐obese diabetic (NOD) mouse: implications for human type 1 diabetes

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Diabetes/Metabolism Research Reviews

• Publication date

  2002-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/dmrr.262PMID 11994902
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of Troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamide

  2006cited by this paper
• Lessons from the glitazones: a story of drug development.

  2001cited by this paper
• Peroxisome proliferator-activated receptors in inflammation control.

  2001cited by this paper
• Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): definition, characterization, and potential prevention.

  2001cited by this paper
• Beta cell destruction in the development of autoimmune diabetes in the non‐obese diabetic (NOD) mouse

  2000cited by this paper
• Hepatic Failure in a Patient Taking Rosiglitazone

  2000cited by this paper
• The role of conjugation in hepatotoxicity of troglitazone in human and porcine hepatocyte cultures.

  2000cited by this paper
• Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration

  2000cited by this paper
• Nitric oxide production and Fas surface expression mediate two independent pathways of cytokine-induced murine beta-cell damage.

  2000cited by this paper
• Efficacy and Safety of Troglitazone in the Treatment of Lipodystrophy Syndromes

  2000cited by this paper
• Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration.

  2000cited by this paper
• Troglitazone and related compounds: therapeutic potential beyond diabetes.

  2000cited by this paper
• Chronic complications in patients with slowly progressing autoimmune type 1 diabetes (LADA).

  1999cited by this paper
• Troglitazone exhibits immunomodulatory activity on the cytokine production of activated human lymphocytes.

  1999cited by this paper
• Troglitazone prevents insulin dependent diabetes in the non-obese diabetic mouse.

  1998influential reference
• Effect of troglitazone on B cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus.

  1998cited by this paper
• Thiazolidinediones.

  1997cited by this paper
• Leptin- or troglitazone-induced lipopenia protects islets from interleukin 1beta cytotoxicity.

  1997cited by this paper
• Metformin does not alter diabetes incidence in the NOD mouse.

  1997cited by this paper
• Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non‐insulin‐dependent diabetes

  1997cited by this paper
• Troglitazone has a scavenging effect on reactive oxygen species.

  1997cited by this paper
• Thiazolidinediones in the Treatment of Insulin Resistance and Type II Diabetes

  1996cited by this paper
• IFN-gamma gene expression in pancreatic islet-infiltrating mononuclear cells correlates with autoimmune diabetes in nonobese diabetic mice.

  1995cited by this paper
• Vitamin E Delays Diabetes Onset in the Non-Obese Diabetic Mouse

  1994cited by this paper
• Altered gene expression for tumor necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistance.

  1994cited by this paper
• Tumor Necrosis Factor α: A Key Component of the Obesity-Diabetes Link

  1994cited by this paper
• NOD mouse colonies around the world--recent facts and figures.

  1993cited by this paper
• The Animals (Scientific Procedures) (Procedure for Representations) Rules 1986

  1986cited by this paper

• Latent autoimmune diabetes in youth

  2025cites this paper
• PPARγ activation reduces pancreatic beta cell death in type 1 diabetes by decreasing heparanase-dependent insulitis.

  2025cites this paper
• Type 1 diabetes: A new vision of the disease based on endotypes

  2024cites this paper
• Huperzine A as a Potential Therapeutic Drug for Diabetic Nephropathy: Insights from Transcriptome, Metabolome, Microbiome, and Network Pharmacology Analysis.

  2024cites this paper
• New Developments in T Cell Immunometabolism and Therapeutic Implications for Type 1 Diabetes

  2022cites this paper
• PPARs and the Development of Type 1 Diabetes

  2020cites this paper
• Past, present and future of latent autoimmune diabetes in adults

  2020cites this paper
• Chapter 2 Latent Autoimmune Diabetes in Adults

  2019cites this paper
• Characterisation of an immune-modulating peptide secreted by a helminth worm

  2018cites this paper
• Latent Autoimmune Diabetes in Adults

  2018cites this paper
• Elevations in the Fasting Serum Proinsulin–to–C-Peptide Ratio Precede the Onset of Type 1 Diabetes

  2016cites this paper
• Peroxisome Proliferator-activated Receptor-γ Activation Augments the β-Cell Unfolded Protein Response and Rescues Early Glycemic Deterioration and β Cell Death in Non-obese Diabetic Mice*

  2016cites this paper
• Mechanisms of transcriptional regulation in the maintenance of β cell function

  2015cites this paper
• An overview of non-insulin adjunctive therapies for Type 1 diabetes

  2014cites this paper
• Management of Patients with Type 1 Diabetes in the Hospital

  2014cites this paper
• Diabetic mouse models

  2013cites this paper
• Lost in translation: endoplasmic reticulum stress and the decline of β‐cell health in diabetes mellitus

  2013cites this paper
• Effect of Pioglitazone on the Course of New-Onset Type 1 Diabetes Mellitus

  2013influential citation
• 10 Obesity in the Natural History of Type 1 Diabetes Mellitus : Causes and Consequences

  2012cites this paper
• Obesity in the Natural History of Type 1 Diabetes Mellitus: Causes and Consequences

  2011cites this paper
• Interventions for latent autoimmune diabetes (LADA) in adults.

  2011cites this paper
• Rosiglitazone protects diabetic rats from liver destruction

  2011cites this paper
• Type 1 Diabetes - Complications, Pathogenesis, and Alternative Treatments

  2011cites this paper
• Pioglitazone might prevent the progression of slowly progressive type 1 diabetes.

  2009cites this paper
• Rosiglitazone preserves islet beta-cell function of adult-onset latent autoimmune diabetes in 3 years follow-up study.

  2009cites this paper
• Latent autoimmune diabetes of adulthood (LADA): An often misdiagnosed type of diabetes mellitus

  2009cites this paper
• Perfil de expressão de genes modulados pela Pioglitazona em ilhotas pancreáticas murídeas

  2008cites this paper
• Addressing insulin resistance in Type 1 diabetes

  2008cites this paper
• The peroxisomal proliferator-activated receptor gamma isoform 2 (PPARgamma2) is an established susceptibility marker for type 2 diabetes (T2D).

  2008cites this paper
• [Latent autoimmune diabetes of adult or slim type 2 diabetes mellitus?].

  2008cites this paper
• [Adjunctive therapies to glycaemic control of type 1 diabetes mellitus].

  2008cites this paper
• Adjuvantes no tratamento da hiperglicemia do diabetes melito tipo 1

  2008cites this paper
• Diabetes auto-imune latente do adulto ou diabetes melito tipo 2 magro?

  2008cites this paper
• A manutenção do tecido adiposo é fundamental para o controle metabólico do diabetes mellitus induzido em ratos.

  2008cites this paper
• Identification of New Susceptibility Genes for Type 1 Diabetes: An Update

  2008cites this paper
• Efeito da pioglitazona sobre a viabilidade funcional e o índice de apoptose de ilhotas pancreáticas murídeas em cultura

  2008cites this paper
• LETTER TO THE EDITOR

  2008cites this paper
• Randomized, controlled, parallel-group prospective study to investigate the clinical effectiveness of early insulin treatment in patients with latent autoimmune diabetes in adults

  2008influential citation
• Latent autoimmune diabetes in adults (LADA): usefulness of anti-GAD antibody titers and benefit of early insulinization.

  2007cites this paper
• Interventions for latent autoimmune diabetes (LADA) in adults.

  2007cites this paper
• [LADA--latent autoimmune diabetes in adults].

  2007cites this paper
• IRS1, KCNJ11, PPARγ2 and HNF‐1α: do amino acid polymorphisms in these candidate genes support a shared aetiology between type 1 and type 2 diabetes?

  2006cites this paper
• Interventions for latent autoimmune diabetes in adults (LADA)

  2006cites this paper
• Immunomodulation for the Prevention of SPIDDM and LADA

  2006cites this paper
• Clinical review: Type 1 diabetes and latent autoimmune diabetes in adults: one end of the rainbow.

  2006cites this paper
• [Insulin resistance and metabolic syndrome in type 1 diabetes mellitus].

  2006cites this paper
• Thiazolidinediones May Not Reduce Diabetes Incidence in Type 1 Diabetes

  2006cites this paper
• Latent autoimmune diabetes of adulthood

  2005cites this paper
• Insulinotropic and anti-inflammatory effects of rosiglitazone in experimental autoimmune diabetes.

  2005cites this paper
• Latent autoimmune diabetes in adults: definition, prevalence, beta-cell function, and treatment.

  2005cites this paper
• Rosiglitazone combined with insulin preserves islet β cell function in adult‐onset latent autoimmune diabetes (LADA)

  2005cites this paper
• Pleiotropic effects of thiazolidinediones: Taking a look beyond antidiabetic activity

  2004cites this paper
• Analysis of the type 2 diabetes-associated single nucleotide polymorphisms in the genes IRS1, KCNJ11, and PPARG2 in type 1 diabetes.

  2004cites this paper
• Neuroendocrine immuno-ontogeny of the pathogenesis of autoimmune disease in the nonobese diabetic (NOD) mouse.

  2004cites this paper
• Insulin resistance is a risk factor for progression to Type 1 diabetes

  2004cites this paper
• New strategies for basal insulin treatment in type 2 diabetes mellitus.

  2004cites this paper
• Insulin resistance is a risk factor for progression to Type 1 diabetes

  2004cites this paper
• Disulfide-Dependent Multimeric Assembly of Resistin Family Hormones

  2004cites this paper
• Central role of defective apoptosis in autoimmunity.

  2003cites this paper
• Lessons for human diabetes from experimental mouse models

  2003cites this paper
• Insulin resistance as a proinflammatory state: mechanisms, mediators, and therapeutic interventions.

  2003cites this paper
• Prevention of autoimmune diabetes in NOD mice by troglitazone is associated with modulation of ICAM-1 expression on pancreatic islet cells and IFN-gamma expression in splenic T cells.

  2003cites this paper
• REVIEW Central role of defective apoptosis in autoimmunity

  2003cites this paper
• The changing faces of diabetes.

  2003cites this paper
• The potential influence of inflammation and insulin resistance on the pathogenesis and treatment of atherosclerosis-related complications in type 2 diabetes.

  2003cites this paper
• Current literature in diabetes.

  2002cites this paper
• Current literature in diabetes

  2002cites this paper
• Current literature in diabetes

  2001cites this paper